Most articles about minor cannabinoids present a tidy picture. The real literature on CBC is not tidy, and pretending otherwise would be misleading.
A 2019 paper in the British Journal of Pharmacology reported that CBC does not activate CB1 at all, and is instead a selective CB2 agonist with higher efficacy than THC at that receptor. A 2020 paper in Scientific Reports reported the opposite: a CB1 binding affinity of 11 nanomolar, which would make CBC the highest-affinity minor cannabinoid tested, along with functional activity.
Both cannot be right. The likely explanation is assay differences. The 2020 dataset used partial displacement of a radioligand, which its own authors flagged as not directly comparable to a full-displacement measurement. But it is not resolved.
The correct thing to say is that CBC is a CB2-preferring agonist, and that its CB1 activity is disputed between studies. Anyone who states a single confident CBC binding figure is quoting one paper and ignoring the other.
There is a further wrinkle that almost nobody mentions. A 2025 paper showed that the two mirror-image forms of CBC behave differently: one activates CB2 and the other does not. CBC in plant material and synthetic products is not necessarily a single form, so the potency of bulk CBC depends on how it was made.
CBC’s standout property is TRPA1 activation, with an EC50 of 0.09 micromolar. That is among the most potent TRPA1 actions measured for a phytocannabinoid, and it is comparable to CBD’s own TRPA1 activity, so it is a shared strength rather than a point of difference. TRPA1 is a sensory channel involved in detecting irritants and in inflammatory signaling.
Interestingly, when researchers looked at CBC’s anti-inflammatory and gut motility effects in mouse colitis models, those effects went through TRPA1 rather than through cannabinoid receptors. So the cannabinoid receptor argument above may matter less than it appears.
CBC also inhibits cellular uptake of anandamide, one of the body’s own cannabinoids, more effectively than CBD does.
This does not mean CBC is useless. It means nobody knows, and a company selling it should say so plainly rather than filling the gap with mouse studies dressed up as findings.
If you want the compound with human evidence, that is CBD. If you want to try CBC, you are trying something with interesting receptor pharmacology and no clinical data at all, at a dose nobody has characterized.
CBC appears naturally in full-spectrum hemp extracts at low levels. A dedicated CBC product concentrates it. Neither approach has evidence behind it in humans.
Still weighing up the options? See CBC vs CBG, CBN vs CBC or CBD vs CBG vs CBN. For more background, read our guide on the entourage effect. Endoca products related to this comparison: Full-spectrum CBD.
CBC from hemp has been treated as lawful under the 2018 Farm Bill on the same basis as CBD, provided the source material stays under 0.3 percent delta-9 THC by dry weight.
From 12 November 2026 the federal test becomes total THC including THCA, and cannabinoids synthesized outside the plant are excluded. Naturally extracted CBC is not the target of that change. CBC produced synthetically may be. FDA has not yet published the lists needed to apply the rule, more than six months past its statutory deadline.
CBD’s safety profile is characterized, including liver enzyme elevations at therapeutic doses and cytochrome P450 inhibition.
CBC has no human safety data of any kind. Rodent work has not flagged obvious problems, which is not the same as evidence of safety in people.
CBC appears on our full-spectrum certificates of analysis alongside CBD, CBDA, CBG, CBN, THC and THCA. In our extracts it is a genuine minor constituent at low percentage. We report the measured number rather than a target, and we do not build claims on top of it.
No. In animal behavioral testing it produced no cannabis-like effects.
At CB2 and TRPA1, on paper, in cell assays. In terms of anything demonstrated in a person, there is nothing to compare.
Unknown. No human pharmacokinetic or dosing study exists.
Usually in small amounts, yes.
CBC is scarce and difficult to isolate in quantity, and research funding has concentrated on CBD and THC.
CBC is a minor cannabinoid that the hemp plant makes from CBGA, the same precursor that leads to CBD and THC. It is present in much smaller amounts than CBD and is not considered intoxicating.
Not in people. The research on CBC is from cell and animal studies, and there are no published human trials. Any benefit claimed for CBC is a hypothesis, not a finding.
Udoh M, Santiago M, Devenish S, McGregor IS, Connor M. Cannabichromene is a cannabinoid CB2 receptor agonist. Br J Pharmacol 2019;176:4537-4547.
Zagzoog A et al. In vitro and in vivo pharmacological activity of minor phytocannabinoids. Sci Rep 2020;10:20405.
De Petrocellis L et al. Effects of cannabinoids on TRP channels. Br J Pharmacol 2011;163:1479-1494.
Walsh KB, McKinney AE, Holmes AE. Minor Cannabinoids. Front Pharmacol 2021;12:777804.
Udoh M et al. Enantiomers of cannabichromene at CB2. Cannabis Cannabinoid Res 2025;10.
Congressional Research Service. Legal Sidebar LSB11381, updated 22 December 2025.
Last reviewed 1 September 2026.
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.